Description: Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The company's lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The company's product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Home Page: www.verastem.com
VSTM Technical Analysis
117 Kendrick Street
Needham,
MA
02494
United States
Phone:
781 292 4200
Officers
| Name | Title |
|---|---|
| Mr. Brian M. Stuglik BPHARM, R.Ph., RPh | CEO & Director |
| Mr. Daniel W. Paterson | COO & Pres |
| Mr. Richard H. Aldrich M.B.A., Mba | Founder and Consultant |
| Dr. Robert A. Weinberg Ph.D. | Co-Founder & Chair of Scientific Advisory Board |
| Dr. Piyush B. Gupta Ph.D. | Co-Founder |
| Dr. Michelle Dipp M.D., Ph.D. | Co-Founder |
| Mr. Daniel Calkins | Interim Principal Accounting Officer & Financial Officer |
| Dr. Jonathan Pachter Ph.D. | Chief Scientific Officer |
| Ms. Erin S. Cox | Sr. Director of Investor Relations & Corp. Communications |
| Mr. Sean C. Flynn | VP, Gen. Counsel & Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5037 |
| Price-to-Sales TTM: | 51.8406 |
| IPO Date: | 2012-01-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 48 |